AbbVie (ABBV)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
At a market value of $485.5B, AbbVie's free cash flow of $17.8B (fiscal 2025) would need to grow about 9% a year for the stock to be worth today's price. That is close to what the company has delivered over the last 9 years.
Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from AbbVie's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.
Fundamental grade
Five factors scored 1 to 9 from ABBV's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from AbbVie's 10-K filings. The deep dive has 15+ years, quarters and every line.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B |
| Net income | $11.5B | $11.8B | $4.9B | $4.3B | $4.2B |
| Free cash flow | $22.0B | $24.2B | $22.1B | $17.8B | $17.8B |
| EPS (diluted) | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 |
| Operating margin | 31.9% | 31.2% | 23.5% | 16.2% | 24.6% |
Where the revenue comes from
Revenue by regions, fiscal 2025.
Superinvestors who own ABBV
From each investor's latest 13F filing (what a 13F shows). 10 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Cliff Asness AQR Capital Management |
Added | $507M | 0.18% | Q2 2026 |
| Larry Robbins Glenview Capital Management |
New position | $37M | 0.68% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Added | $27M | 0.06% | Q2 2026 |
| Hersh Cohen ClearBridge Investments |
Trimmed | $21M | 0.02% | Q2 2026 |
| Eric Marshall Hodges Capital Management |
Trimmed | $5M | 0.33% | Q2 2026 |
| Murray Stahl Horizon Kinetics LLC |
Trimmed | $5M | 0.05% | Q2 2026 |
| Mario Gabelli GAMCO Investors |
Trimmed | $3M | 0.03% | Q2 2026 |
| Dodge & Cox Dodge & Cox |
Held | $3M | 0.00% | Q2 2026 |
| Bill Nygren Harris Associates LP |
Trimmed | $608,969 | 0.00% | Q2 2026 |
| David Iben Kopernik Global Investors |
Held | $33,580 | 0.00% | Q2 2026 |
Insider buying
Open-market purchases by AbbVie's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Feb 5, 2026 | Ro Khanna |
0 | $218.44 | — |
| Feb 5, 2026 | Ro Khanna |
0 | $218.44 | — |
| Jan 23, 2026 | Ro Khanna |
0 | $219.21 | — |
| Jan 23, 2026 | Ro Khanna |
0 | $219.21 | — |
| Oct 30, 2025 | Lisa C. Mcclain |
0 | $228.35 | — |
| Oct 30, 2025 | Lisa C. Mcclain |
0 | $228.35 | — |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when ABBV trades at or below it.
Free accounts get 3 price alerts. No card needed.
In the full deep dive
Questions
What growth does AbbVie's stock price imply?
At a market value of $485.5B, AbbVie would need its free cash flow to grow about 9% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 12% a year.
Are AbbVie insiders buying the stock?
6 open-market insider purchases of ABBV in the last 12 months, from SEC Form 4 filings.
Which superinvestors own AbbVie?
10 of the superinvestors Investingly tracks hold ABBV in their latest 13F, including Cliff Asness, Larry Robbins, Joel Greenblatt.
Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.